Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | The role of BTK inhibitors in the treatment of MCL: ongoing trials and future outlooks

In this discussion, Tycel Phillips, MD, City of Hope, Duarte, CA, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, give an overview of the current role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). These agents have shown promise in the relapsed/refractory (R/R) setting, and several trials are continuing to explore the efficacy of BTKis in this disease. Dr Phillips and Dr Kamdar comment on the role of both covalent and non-covalent BTKis, and share their thoughts on the sequencing of these agents with other therapies. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.